Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation.

× No keyword cloud information.

15 in total

Review 1. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application.

Authors: Jerrold R Turner
Journal: Am J Pathol Date: 2006-12 Impact factor: 4.307

2. The 55-kD tumor necrosis factor receptor and CD95 independently signal murine hepatocyte apoptosis and subsequent liver failure.

Authors: M Leist; F Gantner; G Künstle; I Bohlinger; G Tiegs; H Bluethmann; A Wendel
Journal: Mol Med Date: 1996-01 Impact factor: 6.354

Review 3. New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity.

Authors: Hirofumi Ochi; Michal Abraham; Hiroki Ishikawa; Dan Frenkel; Kaiyong Yang; Alexandre Basso; Henry Wu; Mei-Ling Chen; Roopali Gandhi; Ariel Miller; Ruth Maron; Howard L Weiner
Journal: J Neurol Sci Date: 2008-09-18 Impact factor: 3.181

4. The chemokine receptor CCR7 is a promising target for rheumatoid arthritis therapy.

Authors: Georgios L Moschovakis; Anja Bubke; Michaela Friedrichsen; Jasmin Ristenpart; Jaap Willem Back; Christine S Falk; Elisabeth Kremmer; Reinhold Förster
Journal: Cell Mol Immunol Date: 2018-07-04 Impact factor: 11.530

5. Optimization of whole-cell vaccines with CpG/αOX40/cGAMP to strengthen the anti-tumor response of CD4⁺ T cells in melanomas.

Authors: Xuedan Du; Jinting Wu; Ye Zhao; Bin Wang; Xiaobo Ding; Qiuyan Lin; Yingyu Chen; Jinduo Zhao; Lixiao Liu; Xiaolu Mao; Zhen Fang; Chunhong Zhang; Wenfeng Li
Journal: J Cancer Res Clin Oncol Date: 2022-06-24 Impact factor: 4.322

The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation.

Review 1. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application.

2. The 55-kD tumor necrosis factor receptor and CD95 independently signal murine hepatocyte apoptosis and subsequent liver failure.

Review 3. New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity.

4. The chemokine receptor CCR7 is a promising target for rheumatoid arthritis therapy.

5. Optimization of whole-cell vaccines with CpG/αOX40/cGAMP to strengthen the anti-tumor response of CD4⁺ T cells in melanomas.

6. No static at all.

Review 7. Treatment of type 1 diabetes with anti-T-cell agents: from T-cell depletion to T-cell regulation.

8. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

Review 9. Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation?

10. Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice.

The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation.

Review 1. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application.

2. The 55-kD tumor necrosis factor receptor and CD95 independently signal murine hepatocyte apoptosis and subsequent liver failure.

Review 3. New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity.

4. The chemokine receptor CCR7 is a promising target for rheumatoid arthritis therapy.

5. Optimization of whole-cell vaccines with CpG/αOX40/cGAMP to strengthen the anti-tumor response of CD4+ T cells in melanomas.

6. No static at all.

Review 7. Treatment of type 1 diabetes with anti-T-cell agents: from T-cell depletion to T-cell regulation.

8. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

Review 9. Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation?

10. Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice.

5. Optimization of whole-cell vaccines with CpG/αOX40/cGAMP to strengthen the anti-tumor response of CD4⁺ T cells in melanomas.